Mark Douglas

Mark brings more than 17 years of biotech experience to Jnana working in multiple chemistry, manufacturing and controls (CMC) roles from pre-IND to NDA and post-commercial optimization. Prior to Jnana, Mark was the head of CMC at MapLight Therapeutics where he led the pharmaceutical development of multiple small-molecule assets in CNS disorders, including an extended-release fixed-dose combination product. During his time at MapLight, he guided the team through a period of significant growth and was part of multiple successful regulatory submissions. Prior to MapLight, Mark helped launch Zilretta^® at Flexion Therapeutics and led post-commercialization process optimization and scale-up efforts and spent over nine years at Infinity Pharmaceuticals holding roles of increasing responsibility in CMC and translational science. Mark holds a master’s degree in pharmaceutical science from Northeastern University and a B.S. in chemistry from Eastern Nazarene College.